This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Naluzotan
- DrugBank Accession Number
- DB05562
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Naluzotan (DB05562)
- Weight
- Average: 450.64
Monoisotopic: 450.266462274 - Chemical Formula
- C23H38N4O3S
- Synonyms
- Naluzotan
- External IDs
- PRX-00023
Pharmacology
- Indication
Investigated for use/treatment in anxiety disorders and depression.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism U5-hydroxytryptamine receptor 1A agonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Naluzotan is combined with 1,2-Benzodiazepine. Acebutolol Naluzotan may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when Naluzotan is combined with Aceclofenac. Acemetacin The risk or severity of hypertension can be increased when Naluzotan is combined with Acemetacin. Acenocoumarol The risk or severity of adverse effects can be increased when Naluzotan is combined with Acenocoumarol. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Naluzotan. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with Naluzotan. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Naluzotan. Aclidinium Naluzotan may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. Agomelatine The risk or severity of adverse effects can be increased when Naluzotan is combined with Agomelatine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- Phenylpiperazines
- Alternative Parents
- N-arylpiperazines / Acetanilides / N-acetylarylamines / Dialkylarylamines / Aniline and substituted anilines / N-alkylpiperazines / Organosulfonamides / Organic sulfonamides / Acetamides / Aminosulfonyl compounds show 7 more
- Substituents
- Acetamide / Acetanilide / Amine / Amino acid or derivatives / Aminosulfonyl compound / Anilide / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Benzenoid show 26 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- LQ54E5B4EW
- CAS number
- 740873-06-7
- InChI Key
- SPWZXWDPAWDKQE-UHFFFAOYSA-N
- InChI
- InChI=1S/C23H38N4O3S/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24H,2-6,8-9,12-17,19H2,1H3,(H,25,28)
- IUPAC Name
- N-(3-{4-[4-(cyclohexylmethanesulfonamido)butyl]piperazin-1-yl}phenyl)acetamide
- SMILES
- CC(=O)NC1=CC=CC(=C1)N1CCN(CCCCNS(=O)(=O)CC2CCCCC2)CC1
References
- General References
- Not Available
- External Links
- ChemSpider
- 9605731
- BindingDB
- 50187377
- ChEMBL
- CHEMBL209821
- ZINC
- ZINC000003963096
- Wikipedia
- Naluzotan
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Anxiety Disorders 1 2 Completed Treatment Major Depressive Disorder (MDD) 1 2 Terminated Treatment Epilepsies / Epilepsy, Localization Related / Temporal Lobe Epilepsy (TLE) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0489 mg/mL ALOGPS logP 2.68 ALOGPS logP 2.53 ChemAxon logS -4 ALOGPS pKa (Strongest Acidic) 11.08 ChemAxon pKa (Strongest Basic) 7.64 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 81.75 Å2 ChemAxon Rotatable Bond Count 9 ChemAxon Refractivity 127.77 m3·mol-1 ChemAxon Polarizability 51.92 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
- Gene Name
- HTR1A
- Uniprot ID
- P08908
- Uniprot Name
- 5-hydroxytryptamine receptor 1A
- Molecular Weight
- 46106.335 Da
References
- Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC Jr, Donahue SR, Kauffman M, Iyer GR, Reinhard JF Jr: Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008 Apr;28(2):235-9. doi: 10.1097/JCP.0b013e31816774de. [Article]
- de Paulis T: Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression. Curr Opin Investig Drugs. 2007 Jan;8(1):78-86. [Article]
- Iyer GR, Reinhard JF Jr, Oshana S, Kauffman M, Donahue S: Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects. J Clin Pharmacol. 2007 Jul;47(7):817-24. doi: 10.1177/0091270007300953. Epub 2007 May 10. [Article]
Drug created at November 18, 2007 18:26 / Updated at February 21, 2021 18:51